April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Multi-Center Study of a New Home AMD Perimeter, Based on Preferential Hyperacuity, for Early Detection of CNV
Author Affiliations & Notes
  • A. Loewenstein
    Ophthalmology, Tel-Aviv Medical Center, Tel Aviv, Israel
  • J. Ferencz
    Ophthalmology, Sapir Medical Center, Kefar Sabba, Israel
  • Y. Lang
    Ophthalmology, Haemek Medical Center, Afula, Israel
  • I. Yeshurun
    Ophthalmology, Wolfson Medical Center, Holon, Israel
  • A. Pollack
    Ophthalmology, Kaplan Medical Center, Rehovot, Israel
  • R. Siegal
    Ophthalmology, Rabin Medical Center, Petah Tikva, Israel
  • J. Karp
    Ophthalmology, Machon Mor Medical Center, Kiryat Byalik, Israel
  • T. Lifshitz
    Ophthalmology, Soroka Medical Center, Beer Sheva, Israel
  • Footnotes
    Commercial Relationships  A. Loewenstein, Notal Vision, C; J. Ferencz, None; Y. Lang, None; I. Yeshurun, None; A. Pollack, None; R. Siegal, None; J. Karp, None; T. Lifshitz, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 1660. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Loewenstein, J. Ferencz, Y. Lang, I. Yeshurun, A. Pollack, R. Siegal, J. Karp, T. Lifshitz; Multi-Center Study of a New Home AMD Perimeter, Based on Preferential Hyperacuity, for Early Detection of CNV. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1660.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : A new home Macular Perimeter (HMP), based on the technology of preferential hyperacuity perimetry, was recently developed for the purpose of monitoring AMD patients. The aim of this study was to evaluate the sensitivity and specificity of this device in detection of CNV.

Methods: : Patients with intermediate AMD or recent (developed within 2 months) CNV , performed an HMP examination and underwent biomicroscopy, color stereoscopic photography or fluorescein angiography. Grading, masked to the HMP results, was performed by two retina specialists.

Results: : 77 patients were enrolled to the study. Of 43 patients with Intermediate AMD, 36 were true positive on the HMP, yielding a specificity of 84% (95% [CI] ±10%). Of 34 CNV patients, 29 were true positive on the HMP, yielding a sensitivity of 85% (95% [CI] ±12%). Sensitivity was not significantly different for sub-foveal (n=18) and non subfoveal (n=16) lesions (CHI-square test, p = 0.53), nor for occult (n=25) or classic (n=8) lesions (CHI-square test, p = 0.81).

Conclusions: : The HMP has high specificity and sensitivity in differentiating CNV from intermediate AMD eyes, with a sensitivity that is independent of location or type of CNV lesion. At home this new diagnostic device can be used frequently. It therefore holds promise for earlier detection of CNV and better final outcome following treatment.

Clinical Trial: : www.clinicaltrials.gov NCT00359008

Keywords: age-related macular degeneration • choroid: neovascularization • retinal neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.